MX2009012272A - Vectores para la expresion de genes multiples. - Google Patents

Vectores para la expresion de genes multiples.

Info

Publication number
MX2009012272A
MX2009012272A MX2009012272A MX2009012272A MX2009012272A MX 2009012272 A MX2009012272 A MX 2009012272A MX 2009012272 A MX2009012272 A MX 2009012272A MX 2009012272 A MX2009012272 A MX 2009012272A MX 2009012272 A MX2009012272 A MX 2009012272A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid molecule
vectors
gene expression
multiple gene
Prior art date
Application number
MX2009012272A
Other languages
English (en)
Spanish (es)
Inventor
Nathalie Silvestre
Doris Schmitt
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of MX2009012272A publication Critical patent/MX2009012272A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/863Poxviral vectors, e.g. entomopoxvirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009012272A 2007-05-15 2008-01-29 Vectores para la expresion de genes multiples. MX2009012272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07360019 2007-05-15
PCT/EP2008/051031 WO2008138648A1 (en) 2007-05-15 2008-01-29 Vectors for multiple gene expression

Publications (1)

Publication Number Publication Date
MX2009012272A true MX2009012272A (es) 2009-12-01

Family

ID=39522406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012272A MX2009012272A (es) 2007-05-15 2008-01-29 Vectores para la expresion de genes multiples.

Country Status (16)

Country Link
US (1) US8337859B2 (enExample)
EP (1) EP2162544B1 (enExample)
JP (1) JP5474767B2 (enExample)
KR (1) KR101514473B1 (enExample)
CN (1) CN101688223B (enExample)
AR (1) AR065075A1 (enExample)
AU (1) AU2008250520B2 (enExample)
BR (1) BRPI0810305A2 (enExample)
CA (1) CA2686772C (enExample)
ES (1) ES2416361T3 (enExample)
IL (1) IL201963A (enExample)
MX (1) MX2009012272A (enExample)
PE (1) PE20090483A1 (enExample)
RU (1) RU2462513C2 (enExample)
TW (1) TW200844231A (enExample)
WO (1) WO2008138648A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415462B2 (en) 2007-05-15 2013-04-09 Transgene S.A. Signaling peptides
US9206440B2 (en) 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
RU2555346C2 (ru) * 2009-08-07 2015-07-10 Трансген Са Композиция для лечения инфекции вирусом гепатита в
WO2011127924A2 (de) * 2010-04-16 2011-10-20 Charité - Universitätsmedizin Berlin Mittel zur lokalen behandlung von zervixdysplasien
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
US9216213B2 (en) * 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
US9492526B2 (en) * 2012-01-24 2016-11-15 Sanford Health Polynucleotides for treating oncogenic viral polypeptide positive tumors
RU2684211C2 (ru) 2013-02-21 2019-04-04 Тёрнстоун Лимитед Партнершип Композиция вакцины
SG11201702611YA (en) * 2014-10-14 2017-04-27 Univ Pennsylvania Combination therapy for use in cancer therapy
KR102833333B1 (ko) 2016-01-08 2025-07-11 니코데 테라퓨틱스 에이에스에이 치료적 항암 네오에피토프 백신
EP3452087A1 (en) * 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
BE1024774B1 (fr) * 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
CN113227361B (zh) * 2018-11-21 2024-12-20 梅奥医学教育及研究基金会 腺病毒和使用腺病毒的方法
KR20240086779A (ko) * 2022-12-05 2024-06-19 경상국립대학교산학협력단 다중 단백질의 발현을 위한 신규 핵산 구조체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
CA2295309A1 (en) 1997-06-30 1999-01-07 Nippon Kayaku Kabushiki Kaisha Novel naphthyridine derivatives or salts thereof
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2774699B1 (fr) 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
JP4799789B2 (ja) * 1999-08-25 2011-10-26 メルク・シャープ・エンド・ドーム・コーポレイション ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
EP1427443A4 (en) 2001-08-23 2006-03-08 Merck & Co Inc VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR
EP1407033B1 (en) * 2002-05-16 2006-01-11 Bavarian Nordic A/S Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
AU2008209759B2 (en) * 2007-01-30 2013-03-21 Transgene S.A. Papillomavirus E2 polypeptide used for vaccination

Also Published As

Publication number Publication date
BRPI0810305A2 (pt) 2018-07-10
WO2008138648A1 (en) 2008-11-20
CA2686772A1 (en) 2008-11-20
KR101514473B1 (ko) 2015-04-22
US8337859B2 (en) 2012-12-25
IL201963A (en) 2013-09-30
CA2686772C (en) 2015-03-24
US20100303838A1 (en) 2010-12-02
IL201963A0 (en) 2011-08-01
AU2008250520B2 (en) 2013-10-31
AR065075A1 (es) 2009-05-13
TW200844231A (en) 2008-11-16
CN101688223B (zh) 2013-07-31
PE20090483A1 (es) 2009-05-20
ES2416361T3 (es) 2013-07-31
JP5474767B2 (ja) 2014-04-16
RU2009144898A (ru) 2011-06-20
HK1135731A1 (en) 2010-06-11
AU2008250520A1 (en) 2008-11-20
KR20100019432A (ko) 2010-02-18
EP2162544A1 (en) 2010-03-17
JP2010526547A (ja) 2010-08-05
EP2162544B1 (en) 2013-04-17
RU2462513C2 (ru) 2012-09-27
CN101688223A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
MX2009012272A (es) Vectores para la expresion de genes multiples.
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MY156855A (en) Novel regulatory elements
MX346215B (es) Gen plaguicida axmi-205 y metodos para su uso.
MX2014001070A (es) Gen plaguicida axmi279 y sus metodos de uso.
BR112012020705A2 (pt) axmi221z, axmi222z, axmi224z, e axmi225z genes de delta-endotoxina e métodos para sua utilização.
MX2011003229A (es) Terapia genica con porfobilinogeno desaminasa.
MX2014000993A (es) Gen de la toxina axmi270 y sus metodos de uso.
NZ603901A (en) Vectors and sequences for the treatment of diseases
PH12015500549A1 (en) Hppd variants and methods of use
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
MX2012001426A (es) Familia de genes plaguicidas axmi-192 y metodos para su uso.
WO2010075498A3 (en) Axmi-150 delta-endotoxin gene and methods for its use
MY175477A (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
MY162210A (en) Pharmaceutical composition
NZ604915A (en) Recombinant production of steviol glycosides
MX2009000656A (es) Acidos nucleicos que se fijan a sdf-i.
MX362999B (es) Gen de la delta-endotoxina axmi345 y sus metodos de uso.
GB201201178D0 (en) Novel enzymes
BRPI0806252A2 (pt) molécula de ácido nucléico de promotor, vetor recombinante, célula de hospedeiro e método de expressão de gene alvo
EA033285B1 (ru) Варианты белков axmi205 и способы их применения
HK1198170A1 (en) Pseudomonas exotoxin a with less immunogenic b cell epitopes
AU2012358181A8 (en) Compositions and methods for the delivery of biologically active RNAs
MX362455B (es) Gen de la toxina axmi335 de bacillus thuringiensis y sus metodos de uso.
WO2010046493A3 (en) Gene transfer vectors comprising at least one isolated dna molecule having insulator and or boundary properties and methods to identify the same

Legal Events

Date Code Title Description
FG Grant or registration